Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105898173 | 10589817 | 3 | F | 20160704 | 20141118 | 20160706 | EXP | CN-ROCHE-1490882 | ROCHE | , GU J, ZHANG Q, LIU L, WANG J, LI X, LUO J, HERNANDEZ-ILIZALITURRI F, FERNANDEZ S, CZUCZMAN M, CAO J, HONG X AND GUO Y. CARDIOTOXICITY AS INDICATED BY LVEF AND TROPONIN T SENSITIVITY FOLLOWING TWO ANTHRACYCLINE-BASED REGIMENS IN LYMPHOMA: RESULTS FROM A RANDOMIZED PROSPECTIVE CLINICAL TRIAL. ONCOTARGET 2016 MAY 31;7 (22):32519-32531. | 0.00 | Y | 0.00000 | 20160706 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105898173 | 10589817 | 1 | PS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | U | NOT REPORTED | 103705 | SOLUTION FOR INFUSION | ||||||||
| 105898173 | 10589817 | 2 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | U | 0 | ||||||||||
| 105898173 | 10589817 | 3 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | U | 0 | ||||||||||
| 105898173 | 10589817 | 4 | SS | PREDNISONE. | PREDNISONE | 1 | Unknown | U | 0 | ||||||||||
| 105898173 | 10589817 | 5 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | U | 0 | ||||||||||
| 105898173 | 10589817 | 6 | SS | EPIRUBICIN | EPIRUBICIN | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105898173 | 10589817 | 1 | Diffuse large B-cell lymphoma |
| 105898173 | 10589817 | 2 | Diffuse large B-cell lymphoma |
| 105898173 | 10589817 | 3 | Diffuse large B-cell lymphoma |
| 105898173 | 10589817 | 4 | Diffuse large B-cell lymphoma |
| 105898173 | 10589817 | 5 | Diffuse large B-cell lymphoma |
| 105898173 | 10589817 | 6 | Diffuse large B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105898173 | 10589817 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105898173 | 10589817 | Ejection fraction decreased | |
| 105898173 | 10589817 | Hepatic function abnormal | |
| 105898173 | 10589817 | Neutropenia | |
| 105898173 | 10589817 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |